Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
Key Highlights
- ➤New U.S. patent protects Symvess manufacturing, sterilization, storage and shipping through 2043
- ➤Humacyte plans supplemental BLA this year seeking dialysis-access indication for Symvess
- ➤Symvess received FDA approval in December 2024 for vascular trauma indication
Expert Statements
Laura Niklason, Founder, President and Chief Executive Officer of Humacyte
“The issuance of this patent significantly strengthens our intellectual property portfolio by extending protection for key aspects of our bioengineering platform into 2043”
Laura Niklason, Founder, President and Chief Executive Officer of Humacyte
“The extended term of this new patent provides long-term protection for key aspects of our technology and enhances our ability to create sustainable value as we aim to advance our next-generation regenerative medicine products toward broader clinical and commercial adoption.”
– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped.
DURHAM, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the issuance of a new U.S. patent covering key aspects of the manufacturing, sterilization, storage and shipping of Symvess® (the acellular tissue engineered vessel, or ATEV) and other bioengineered human tissues. U.S. Patent No. 12,742,144, titled “Systems, Devices and Methods for Engineered Tissue Construct Transport and Containment” provides protection into 2043 and complements a family of existing patents and patent applications encompassing the design and composition of Humacyte’s products and their methods of manufacture.
Get started
Create a free account to read the full story.